|
|
|
Vol. 13, No. 6, pp. 740-753, March 15, 1999
1 Institut de Génétique Moléculaire, Centre National de la Recherche Scientifique (CNRS), F34293 Montpellier Cedex 5, France; 2 Centre de Biologie du Développement, CNRS, Université Paul Sabatier, F31062 Toulouse, France
| |
Abstract |
|---|
|
|
|---|
Specific recognition of splice sites within metazoan mRNA precursors (pre-mRNAs) is a potential stage for gene regulation by alternative splicing. Splicing factors of the SR protein family play a major role in this regulation, as they are required for early recognition of splice sites during spliceosome assembly. Here, we describe the characterization of RSF1, a splicing repressor isolated from Drosophila, that functionally antagonizes SR proteins. Like the latter, RSF1 comprises an amino-terminal RRM-type RNA-binding domain, whereas its carboxy-terminal part is enriched in glycine (G), arginine (R), and serine (S) residues (GRS domain). RSF1 induces a dose-sensitive inhibition of splicing for several reporter pre-mRNAs, an inhibition that occurs at the level of early splicing complexes formation. RSF1 interacts, through its GRS domain, with the RS domain of the SR protein SF2/ASF and prevents the latter from cooperating with the U1 small nuclear ribonucleoprotein particle (U1 snRNP) in binding pre-mRNA. Furthermore, overproduction of RSF 1 in the fly rescues several developmental defects caused by overexpression of the splicing activator SR protein B52/ SRp55. Therefore, RSF1 may correspond to the prototypical member of a novel family of general splicing repressors that selectively antagonize the effect of SR proteins on 5' splice-site recognition.
[Key Words: pre-mRNA splicing; RNA-binding proteins; SF2/ASF; U1 snRNP; RSF1; B52/SRp55]
| |
Introduction |
|---|
|
|
|---|
Pre-mRNA splicing is an essential step in the expression of most
metazoan protein-coding genes, often regulated in a cell-type specific
or developmental manner. The precision and efficiency of the splicing reaction result from a dynamic series of interactions among the U1, U2, U4/U6, and U5 small nuclear
ribonucleoprotein (snRNP) particles, non-snRNPs, and the pre-mRNA that
lead to the formation of the spliceosome, the ribonucleoprotein
structure in which the accurate excision of intervening sequences
(introns) takes place (Sharp 1994
; Krämer 1996
; Staley and
Guthrie 1998
). Although most of the biochemical events involved in
constitutive pre-mRNA splicing are being elucidated, the complex
regulation underlying the selection of alternative exons is less well
understood (Adams et al. 1996
; Wang and Manley 1997
). Both structural
features and sequence content of pre-mRNAs appear to be involved (Green 1991
). In the past few years, a class of purine-rich exonic elements known as exonic splicing enhancers (ESEs) has been identified in a
number of pre-mRNAs (Katz and Skalka 1990
; Lavigueur et al. 1993
; Sun
et al. 1993a
,b
; Watakabe et al. 1993
; Xu et al. 1993
; Caputi et al.
1994
; Dirksen et al. 1994
, 1995
; Tanaka et al. 1994
; Ramchatesingh et
al. 1995
; Staffa and Cochrane 1995
; Staffa et al. 1997
). These
sequences are likely to play a critical role in the initial recognition
and pairing of the 5' and 3' splice sites (Tian and Maniatis
1993
; Staknis and Reed 1994
; Berget 1995
). They are expected to bind a
set of RNA-binding proteins among which several members of the SR
protein family are known to influence the splice site choice (Lavigueur
et al. 1993
; Sun et al. 1993b
; Staknis and Reed 1994
; Fu 1995
; Manley
and Tacke 1996
; Liu et al. 1998
).
Members of the highly conserved SR protein family of splicing
regulators (Zahler et al. 1992
; Fu 1995
; Manley and Tacke 1996
), including SRp20/X16/RBP1, SF2/ASF (SRp30a), SC35 (SRp30b), and B52/SRp55 have modular structures that consist of one or
two RNA-recognition motifs (RRMs) and a carboxy-terminal arginine
(R)/serine (S)-rich domain (the so-called RS domain).
They are thought to be essential splicing factors, as SR proteins
individually can complement splicing-deficient cytoplasmic S100
extracts, which lack SR proteins but contain all other factors
necessary for splicing (Ge et al. 1991
; Krainer et al. 1991
; Mayeda et
al. 1992
; Zahler et al. 1992
; Cavaloc et al. 1994
). Both the RRM and
the RS domains are essential for the function of SR proteins as
splicing factors (Zamore et al. 1992
; Càceres and Krainer 1993
;
Zuo and Manley 1993
; Wang et al. 1998
). The RS domain is responsible
for specific protein-protein interactions among RS domain-containing
proteins (Wu and Maniatis 1993
; Amrein et al. 1994
; Kohtz et al. 1994
;
Zuo and Maniatis 1996
), interactions thought to constitute a bridge
between 5' and 3' splice sites during splice-site selection.
Such protein contacts promote the binding of U1 snRNP to the 5'
splice site and U2 snRNP auxiliary factor 65-kD subunit
(U2AF65) to the 3' splice site at earliest stages of
spliceosome assembly (Staknis and Reed 1994
; Reed 1996
). At least where
introns with weak 3' splice sites are involved, binding of SR
proteins to an ESE may facilitate 3' splice-site complex formation
through interaction with U2AF (Zuo and Maniatis 1996
).
Many of the SR proteins described previously can affect usage of
alternative 5' or 3' splice sites in a concentration-dependent manner (Ge and Manley 1990
; Krainer et al. 1990
; Tian and Maniatis 1993
; Zahler et al. 1993
; Càceres et al. 1994
; Reed 1996
). Both in vitro and in vivo, a small increase in the concentration of SF2/ASF prevents the inappropriate exon-skipping of
certain premRNAs (Mayeda and Krainer 1992
; Mayeda et al. 1993
). It
has been shown also that high levels of SF2/ASF regulate
alternative splicing by promoting the use of proximal versus distal
5' splice sites (Ge and Manley 1990
; Krainer et al. 1990
).
Additionally, targeted disruption of SF2/ASF in chicken
cells demonstrated that SF2/ASF is required for
viability, and this depletion of SF2/ASF affects splicing
of specific transcripts in vivo (Wang et al. 1996
; Wang and Manley
1997
). Similarly, mutants of the B52 gene are homozygous lethal in Drosophila (Ring and Lis 1994
) and overexpression of the B52/SRp55 protein causes severe phenotypes (Kraus and
Lis 1994
). Therefore, the relative abundance of each SR protein
and/or the molar ratio of each SR protein to selective
antagonists may determine the patterns of alternative splicing of many
genes expressed in a particular cell type. In agreement with this, it
has been observed that the relative amount of individual SR proteins
varies in different tissues (Zahler et al. 1993
). As an example, the expression of mouse X16 mRNA is high in thymus, spleen, and
testes but is low or undetectable in liver, kidney, brain, and heart (Zahler et al. 1993
). Similarly, variable levels of X16 and
SC35 mRNAs are expressed in different cell lines and stages of
development (Ayane et al. 1991
; Vellard et al. 1992
). The finding that
competing levels of the heterogeneous nuclear ribonucleoprotein (hnRNP) particle protein A1 could have opposing effects on
SF2/ASF (Mayeda and Krainer 1992
; Mayeda et al. 1993
;
Càceres et al. 1994
) led to the suggestion that the regulation of
the expression of a wide variety of genes by alternative splicing may
be accomplished at least in part by variation in the nuclear
concentration of antagonistic splicing factors. Identification and
characterization of splicing factors that counteract SR proteins may
therefore be an important step in understanding the mechanism for
regulation of gene expression by alternative splicing.
By adopting an oligonucleotide-directed molecular approach to seek for
RNA-binding proteins possibly involved in important developmental
decisions, we have identified three novel D. melanogaster RRM
superfamily proteins previously [referred to as Rox proteins (Brand et
al. 1995
)], among which Rox21, renamed here RSF1 (for repressor splicing
factor 1), exhibits extensive sequence
identity (54%-58%) in its single amino-terminal RRM with members of
the SR protein family. RSF1 also possesses a carboxy-terminal domain enriched in glycine (G), arginine, and serine residues (GRS domain). Here we show that the latter domain mediates specific interactions with
itself and with members of the SR protein family. However, in vitro
complementation assays show that RSF1 inhibits splicing of several
reporter premRNAs, an inhibition that can be selectively counteracted by purified SR proteins. These studies, together with the
finding that RSF1 acts as an SR protein antagonist in vivo, represent
the first identification of a general splicing repressor.
| |
Results |
|---|
|
|
|---|
RSF1 inhibits splicing by competing with the SR proteins
The structural features of RSF1, its nuclear localization, and
association with a subset of actively transcribed regions of giant
polytene chromosomes (data not shown) prompted us to seek a role of
this protein in pre-mRNA splicing. Our initial attempts to do this were
based on complementation experiments using a HeLa nuclear extract
containing a low level of SR proteins, knowing that RSF1 fails to have
the ability of SR protein to restore the splicing activity of the S100
extract (data not shown). To assess the effect of RSF1 on pre-mRNA
splicing, we first used a model
-globin
pre-mRNA substrate (
-3A1) that has three copies of a high-affinity
binding site for RSF1 established by SELEX analysis (E. Labourier, E. Allemand, S. Brand, M. Fostier, J. Tazi, and H.-M. Bourbon, unpubl.),
inserted 20 bases downstream of the first intron of
-globin. This reporter pre-mRNA substrate was
spliced efficiently in a HeLa nuclear extract (Fig. 2A, lanes 2,14, below). However, when this preparation of HeLa nuclear extract was
supplemented with an excess of purified recombinant glutathione
S-transferase (GST)-RSF1 fusion protein produced in
Escherichia coli (Fig. 1, lane 3), splicing
was readily inhibited in a dose-dependent manner (Fig. 2A, lanes
3,4). One trivial explanation, that the recombinant protein preparation contained a component that inhibited splicing, could be eliminated, because GST alone (Fig. 1, lane 1) prepared under
the same conditions had no effect on splicing (Fig. 2A, lanes 11,12).
No inhibition was observed either with heat-denatured GST-RSF1 (data
not shown) or two truncated versions of the protein in which the GRS or
the RRM domain was selectively removed (Figs. 1, lanes 4,5, and 2A,
lanes 5-8). This result demonstrates a requirement for native protein
conformation, as well as for the joint presence of the RRM and the GRS
domain, for the inhibition of splicing. Furthermore, as the
GRS-truncated version (GST-RSF1
C) binds RNA in vitro (E. Labourier, E. Allemand, S. Brand, M. Fostier, J. Tazi, and H.-M.
Bourbon, unpubl.), this joint requirement indicates that splicing
inhibition is not caused by mere nonspecific binding to pre-mRNA.
Additionally, because RSF1 and Drosophila SR protein RBP1 (Kim
et al. 1992
) have homologous RRMs and similar size, we tested the
effect of complementing HeLa nuclear extract with purified GST-RBP1
(Fig. 1, lane 2). This protein had no detectable effect (Fig. 2A, lanes
9,10), even though it binds RNA in vitro (data not shown). Furthermore,
GST-RSF1 inhibits splicing of
-globin pre-mRNA, which does not contain high-affinity RSF1 binding sites (Fig.
2B, lanes 3,4), implying that its splicing inhibition activity in vitro
is not likely to be restricted to reporter pre-mRNAs containing
RSF1-selected sequences. Using native gel electrophoresis to isolate
splicing complexes, we were able to show that the inhibition was at the
level of spliceosome assembly (data not shown). Taken together, our
results support the idea that the inhibition of splicing by GST-RSF1
is related directly to its function as a general splicing repressor
that acts at an early stage of spliceosome assembly.
|
|
Interestingly, a mixture of purified SR proteins (data not shown) or purified SRp30 (Fig. 1, lane 6; note that SRp30 contains both SF2/ASF and SC35 proteins) restored full splicing activity of the RSF1-inhibited HeLa nuclear extract in a concentration-dependent manner (Fig. 2, A, lanes 16 and 17, and B, lanes 10 and 11). Comparison with known amounts of purified SRp30 indicated that our preparation of HeLa nuclear extract contained ~5 pmoles (110 ng) of SRp30 per microliter of extract. The concentration of GST-RSF1 required to achieve complete inhibition of splicing was almost identical (6 pmoles per microliter of extract). A similar quantity of SRp30 was used to restore full splicing activity, suggesting that RSF1 might proceed by competing with SR proteins for the same function.
RSF1 prevents E-complex formation in vitro
The SR proteins are known to promote the earliest stages of the
spliceosome assembly involving the formation of the E (for early) or
commitment complex, in which the 5' splice site is recognized by U1
snRNP and the 3' splice site by binding of U2AF65 at the
pyrimidine tract (Ruskin et al. 1988
; Zamore and Green 1989
; Jamison et
al. 1992
; Michaud and Reed 1993
; Staknis and Reed 1994
; Reed 1996
).
Given that RSF1 acts as a splicing repressor of several reporter
pre-mRNAs, including AdML (data not shown), a model pre-mRNA derived
from the adenovirus major late-transcription unit, we tested whether it
could interfere with the formation of E complex and thereby mediate
splicing inhibition. Previous studies demonstrated that AdML is
assembled into splicing complexes more efficiently than
-globin (Michaud and Reed 1991
); we therefore used this substrate to perform E-complex assembly assays. HeLa cell
nuclear extracts complemented with either purified SRp30 or GST-RSF1
were incubated with 32P-labeled AdML (Michaud and Reed 1991
,
1993
) and assembled RNP complexes were fractionated by gel filtration.
As shown in Figure 3, in contrast to SRp30, which
enhanced the level of E-complex assembly (Fig. 3, cf. I and III).
GST-RSF1 blocked the formation of this complex completely (panels I
and II). However, full E-complex assembly could be restored upon
addition of competing amounts of purified SRp30 to RSF1-inhibited
nuclear extract (data not shown), demonstrating that the inhibition of
splicing by RSF1 was at the level of E-complex assembly.
|
To evaluate the effects of RSF1 on 5' or 3' splice-site
selection, specific complexes were assembled independently on RNAs containing only a 3' or 5' splice site, respectively, as
described (Michaud and Reed 1993
). In agreement with previous studies,
both AdML 5' and 3' half substrates (panels IV and VI,
respectively) gave rise to discrete peaks in the position of E complex
when incubated with HeLa nuclear extract. Although substantial E
complex on the 3' splice site was still detected in extracts
complemented with GST-RSF1 (panel VII, 3.5 pmoles/microliter of extract), little or no E complex was
formed on the 5' splice site (panel V). Inhibition of E complex
formation on the 5' splice site is unlikely to result from
unspecific binding of GST-RSF1 to AdML 5' half substrate because
neither truncated versions of RSF1 nor GST-RBP1 had the same effect
(data not shown). We conclude that RSF1 probably prevents the stable
binding of factor(s) to the 5' splice site but has only slight
effect on the binding of factor(s) to the 3' splice site.
RSF1 impedes stable binding of U1 snRNP at the 5' splice site
The prototypical SR protein SF2/ASF was shown
previously to cooperate with the U1 snRNP particle in forming a stable
complex at the 5' splice site of the model pre-mRNA PIP7.A (Kohtz
et al. 1994
). We therefore tested whether RSF1 could destabilize the binding of U1 snRNP to the 5' splice site. Different combinations of recombinant SF2/ASF, purified U1 snRNP (Fig. 1, lanes
7,11) and GST-RSF1 were incubated with either 32P-labeled
PIP7.A or PIP75'AU, a mutant version that is identical to
PIP7.A, except that the invariant GU dinucleotide at the 5' splice
site is changed to AU (Kohtz et al. 1994
; Jamison et al. 1995
). The
mixes were then analyzed by native gel electrophoresis to resolve the
U1 snRNP-containing complexes from the free probe. No complex was
detected with the mutated substrate (Fig. 4, lane 3),
indicating that an intact, functional 5' splice site is required
for formation of U1 snRNP-SF2/ASF-pre-mRNA complex. In
agreement with previous findings (Kohtz et al. 1994
), U1 snRNP alone
gave rise to low levels of U1 snRNP-pre-mRNA complex formation (lane
2), whereas when both U1 snRNP and SF2/ASF were incubated
with the pre-mRNA a strong complex was detected (lane 5).
Interestingly, GST-RSF1 had no effect on the weak binding of U1 snRNP
to the pre-mRNA (lane 15) but impaired the formation of U1
snRNP-SF2/ASF-pre-mRNA ternary complex dramatically
(lanes 7-9). The GRS domain of RSF1 was required to mediate
inhibition, as a GRS-truncated version of RSF1 was inactive (lane 10).
The GST-RSF1 inhibition was dose dependent; it was almost complete when the ratio between RSF1 and SF2/ASF was nearly
1:1 (lane 9). The possibility that inhibition was caused by
unspecific binding of GST-RSF1 to RNA can be ruled out, because GST
alone (lane 11), or GST-RSF1
C (lane 10) had negligible effects on
ternary complex formation. Furthermore, preassembled ternary complex
was refractory to inhibition by GST-RSF1 (cf. lanes 16 and 18),
suggesting a direct interaction between RSF1 and U1 snRNP and/or SF2/ASF.
|
The GRS domain of RSF1 interacts with the RS domain of SF2/ASF
The RS domain of SF2/ASF is required for the direct
interaction between the latter and the 70K U1 snRNP-specific protein
(U1-70K) and likely mediates the stable binding of U1 snRNP to the
5' splice site. Because this domain is involved in various
selective protein-protein contacts (Wu and Maniatis 1993
; Kohtz et al.
1994
; Lynch and Maniatis 1995
, 1996
), we asked whether specific
inhibition of 5' splice-site recognition could result from specific
binding of this domain with a defined domain of RSF1. To test this,
GST-RSF1 or GST-RSF1
C proteins were immobilized on
glutathione-Sepharose beads and incubated with a purified His-tagged
RS domain of SF2/ASF (Fig. 1, lane 9). Strikingly, the RS
domain of SF2/ASF quantitatively bound to GST-RSF1 (Fig.
5A, lane 4). In contrast, only a background level of
binding, similar to that for beads alone, was detected with
GST-RSF1
C (Fig. 5A, cf. lanes 5 and 6), suggesting that the GRS
domain of RSF1 is essential for binding. Interestingly, a purified
His-tagged GRS domain (Fig. 1, lane 10) exhibited the same
chromatographic behavior as the RS domain (Fig. 5A, lanes 1 and 2),
indicating that RSF1 not only interacts with SF2/ASF but
also with itself. Given that the GRS domain is soluble at high
concentrations (10 mg/ml), it seems unlikely that its
interaction with itself or with the RS domain could be the result of
nonspecific aggregation.
|
To confirm the specificity of these protein-protein interactions
independently and to establish whether RSF1 could bind U1-70K, we
employed Far-Western blotting (Wu and Maniatis 1993
; Kohtz et al.
1994
), which has been used successfully to show specific interactions
between members of the SR protein family and other splicing factors.
After SDS-PAGE analysis, purified proteins were transferred to filters,
renatured, and probed with either 32P-labeled
SF2/ASF or GST-RSF1 (Fig. 5B). The specificity of
binding of modified SF2/ASF or RSF1 was confirmed by
their ability to bind themselves (lanes 1,12), but not to truncated
derivatives deleted for the RS (lanes 2,10) or GRS (lanes 5,13)
domains, respectively. Although, both probes cross-reacted with
immobilized SF2/ASF (lanes 1,9) and GST-RSF1 (lanes
4,12), as well as GST-RBP1 (lanes 7,15), only labeled
SF2/ASF (lane 8), but not GST-RSF1 (lane 16), could decorate the U1-70K band, showing that no binding could occur between
RSF1 and U1-70K. Failure to detect significant recognition between
RSF1 and U1-70K provides further evidence that the observed interaction between GRS and RS domains is specific. Such an interaction is likely to compete with that occurring between SF2/ASF
and U1-70K, thereby interfering with the formation of a stable complex
at the 5' splice site.
RSF1 functionally antagonizes the SR protein B52 in living flies
Previous work has shown that overexpressing B52 protein, also called
SRp55, in a number of cell types affects development and survival of
Drosophila dramatically (Kraus and Lis 1994
) and that the
B52/SRp55 protein can, in vitro, regulate alternative 5' splice-site choice in a concentration-dependent manner. Hence, the ratio of B52/SRp55 to other splicing factors in vivo
might be an important means of regulating alternative splicing. Because developmental Northern blot (RNA) revealed that the RSF1 gene, like the B52/SRp55 gene (Champlin et al. 1991
),
is expressed throughout development (Fig. 6, lanes
1-11) and RSF1 interacts in vitro with B52/SRp55 (Fig. 5B, lane 18), we considered the
possibility that RSF1 is such a splicing factor. Therefore, we assessed
whether RSF1 might functionally antagonize the SR ptotein
B52/SRp55 in a living animal. The GAL4/UAS
binary expression system (Brand et al. 1994
) was used to drive
prolonged high levels of expression of both RSF1 and
B52/SRp55 in a tissue-specific fashion. To this end, the
wild-type RSF1 cDNA was placed within a P-element transposon under transcriptional control of the yeast GAL4-responding upstream activating sequence (UAS-RSF1 element) and 15 independent
UAS-RSF1 transgenic lines were established, using standard
procedures (Spradling and Rubin 1982
). Transgenic flies carrying
UAS-RSF1 and/or UAS-B52 (Kraus and
Lis 1994
) elements were mated to flies that express the yeast
transcriptional activator GAL4 in a cell- or tissue-specific fashion to
drive strong expression of RSF1 and/or
B52/SRp55. To examine the tissue-specific expression of
GAL4 in each cross, lines carrying GAL4 elements were crossed
to a transgenic line carrying the E. coli
-galactosidase-encoding gene under the control of the GAL4
activator (UAS-lacZ; Brand et al. 1994
).
|
Using the GMR-GAL4 (for glass
multimer reporter; Freeman 1996
) line
we directed expression and activity of RSF1 to photoreceptor cells of
the developing eye. Adult progeny consistently showed retinal defects,
the severity of which depended on the UAS-RSF1 transgenic
line employed. Relatively weak defects of retinal development were
observed with UAS-RSF1 lines 5 and 6 (Fig. 7B, cf. b and c,
respectively, with a) compared to line 3 (Fig 7B, d)
which gave rise to eyeless adults. Furthermore, most progeny of lines 5 and 6 were viable (see Table 1) but line 3 offspring
had a strongly decreased viability (~20%). The latter observation
suggests that the GMR element is not entirely eye specific,
and that RSF1 overproduction in tissues other than the eye is lethal.
Although it is difficult to determine the direct cause of this
lethality, it might reflect differences in the levels of RSF1 ectopic
expression owing to different UAS-RSF1 chromosomal
insertions. On increasing the dosage of UAS-RSF1 elements (genotypes
GMR-GAL4/+; UAS-RSF13/UAS-RSF16, and
GMR-GAL4/+; UAS-RSF16/UAS-RSF16) no
viable offspring were observed (Table 1). Furthermore, embryonic lethality was also observed when high uniform expression of RSF1 was
driven by GAL4 under the constitutive daughterless
(da) enhancer (data not shown). Therefore, a correlation exists
between the level of RSF1 overexpression in various tissues and lethality.
|
|
Another fully penetrant phenotype was observed in the progeny of
crosses between UAS-RSF15 and sca-GAL4, a
GAL4-expressing line that accumulates GAL4 activator in precursor cells
of all sensory organs owing to an imaginal disc-specific enhancer of
the scabrous gene (Y.N. Jan, unpubl.; see Fig. 8A for
structure). The adult progeny displayed complete loss
of all bristles (Fig. 8B, cf. a and c). Increasing temperature appears
to enhance the transcriptional activation by GAL4 in
Drosophila (Brand et al. 1994
). On elevating the level of
overexpression of RSF1 by raising the offspring at higher temperatures
(22°C, 25°C, or 28°C), the same phenotypes were aggravated
(data not shown). Note also that mating sca-GAL4 with
UAS-RSF16 gave rise to progeny with late pupal
lethality (Table 1).
|
A previous study concluded that overexpressing B52/SRp55
protein provokes a dominant lethality (Kraus and Lis 1994
). Hence, we
decided to examine the phenotypic consequences of overexpressing B52/SRp55 under the same genetic background used for RSF1
overproduction. Among progeny raised at 22°C, no adult female was
observed when B52/SRp55 overexpression was driven by
GMR-GAL4 (all females died as late pupae) and the rare
eclosed males (<1% of late male pupae) exhibited a fully penetrant
eye phenotype distinct from those observed among the offspring derived
from crosses with the various UAS-RSF1 lines (Fig. 7B; Table
1). However, the progeny from the crosses of flies expressing GAL4 from
sca enhancers to flies carrying the UAS-B52 element
was viable but fails to develop bristles (Fig. 8B; Table 1). Except for
a lower viability, this developmental abnormality was very similar to
the one caused by RSF1 overexpression driven by sca-GAL4
enhancer (Table 1, UAS-RSF15/+;
sca-GAL4/+; Fig. 8B, cf. b and c). Taken
together, these data strongly indicate that a normal level of RSF1 or
B52/SRp55 protein is critical for viability and normal
development of most organs.
Our biochemical data provided evidence for a functional, stoichiometric
antagonism between recombinant RSF1 and SR proteins purified from HeLa
cells (see above). To test this model in vivo, we asked whether
overproduction of RSF1 can rescue some or all of the defects caused by
B52/SRp55 overexpression. Transgenic flies carrying both
a UAS-B52 and a UAS-RSF1 element were crossed with
the GMR-GAL4 transgenic flies. Interestingly, adult progeny of both sexes were obtained, implying that overexpression of RSF1 protein can overcome at least the female lethality and some
developmental defects caused by the overexpression of
B52/SRp55 protein. A trivial GAL4 dosage effect owing to
the presence of two copies of the UAS promoter can be ruled
out, because two copies of the UAS-RSF1 elements lead to more
deleterious developmental defects than one copy alone (Table 1). The
possibility that the overexpression of RSF1 reduces the overexpression
of B52/SRp55 can also be discounted, because quantitative
reverse transcription (RT)-PCR showed that UAS-B52 mRNA
levels, determined at the third-instar larvae, was the same in the
progeny overexpressing B52/SRp55 as in the progeny overexpressing B52/SRp55 and RSF1 (Fig. 7C, panel II, cf.
lanes 3 and 4). Similar UAS-RSF1 mRNA levels were also
observed between progeny overexpressing RSF1 and progeny overexpressing
RSF1 and B52/SRp55 (Fig. 7C, panel II, cf. lanes 2 and
4). Furthermore, Western blot analysis using a monoclonal antibody
(mAb104) that recognizes several SR protein species (Zahler et al.
1992
), defined as SRp20, SRp30a-SRp30b, SRp40, SRp55 (B52), and SRp75,
depending on their apparent molecular weight in SDS gels (Fig. 7C,
panel III, lane 5), detected a strong band at the level of
B52/SRp55 in progeny overexpressing
B52/SRp55 (Fig. 7C, panel III, lanes 3,4) but only very
little in the progeny that do not (Fig. 7C, panel III, lanes 1,2). The
signal of B52/SRp55 did not diminish following
overexpression of RSF1 (Fig. 7C, panel III, cf. lanes 3 and 4),
confirming that RSF1 has no effect on the expression of
B52/SRp55 at the protein level. Given that mAb104
recognized a phosphoepitope (Roth et al. 1991
), it is likely that
overexpressed B52/SRp55 is modified by phosphorylation.
Thus the rescue of the lethal phenotype could be explained by opposite
function of RSF1 and B52/SRp55.
We also analyzed this opposite function when overexpression of RSF1 and B52/SRp55 was driven in another tissue. Although, overexpression of RSF1 under sca-GAL4 enhancer (UAS-RSF16/sca-GAL4) leads to no adults because of late-purpal stage lethality and overexpression of B52/SRp55 (UAS-B52/+; sca-GAL4/+) leads to bristless adults, the progeny of crosses between UAS-B52 + UAS-RSF16 double element lines and sca-GAL4 transgenic flies were viable and had a complete (~10% of the eclosed offspring) or a partial (90% of the eclosed offspring) stereotyped set of apparently normal sensory bristles (Table 1; Fig. 8B, d). Failure to revert complete bristles phenotypes of all progeny flies (~10% had the wild-type phenotype) strongly suggests that the ratio of RSF1 and B52/SRp55 (and/or other SR proteins) may be critical for the normal development of specific organs. Thus, as expected by our model, these in vivo experiments did not reveal functional synergy but rather an antagonism between RSF1 and B52/SRp55; the detrimental effects caused by accumulation of one protein could be partially or fully suppressed by joint accumulation of the other.
| |
Discussion |
|---|
|
|
|---|
RSF1 is a novel splicing regulator that selectively counteracts SR
protein function at the earliest steps of spliceosome assembly, preventing the stable binding of U1 snRNP to pre-mRNA, and thus inactivating 5' splice-site selection. Such an activity is likely to be relevant in vivo to prevent inappropriate SR protein-dependent activation of cryptic and/or weak 5' splice sites
found near exonic enhancer sequences (Watakabe et al. 1993
; Elrick et
al. 1998
). This fits nicely with the ability of RSF1 to bind enhancer
splicing sequences through its RRM (E. Labourier, E. Allemand, S. Brand, M. Fostier, J. Tazi, and H.-M. Bourbon, unpubl.) and to interact via its GRS domain with the RS domain of SR proteins, thereby impairing
the formation of productive splicing complexes.
The observation that RSF1 and SR proteins colocalize in the same
nuclear regions (data not shown) could be attributed to their participation in similar nuclear events. We present evidence that RSF1
can interact directly with SF2/ASF and that the GRS
domain of the former and the RS domain of the latter are required for this interaction. This protein-protein interaction is likely to compete
with those occurring between SR proteins and constitutive factors
involved in the selection of alternative splice sites. Indeed, SR
proteins have been shown to promote the binding of U1 snRNP to the
5' splice site (Eperon et al. 1993
; Kohtz et al. 1994
; Staknis and
Reed 1994
; Zahler and Roth 1995
), most likely through specific
protein-protein interactions between SR proteins and U1-70K (Wu and
Maniatis 1993
; Kohtz et al. 1994
). At least in vitro, we show that RSF1
prevents cooperative interaction between SF2/ASF and
U1-snRNP 70K protein and thus interferes with the stable binding of U1
snRNP at the 5' splice site. RSF1 may have emerged during evolution
as a dominant-negative SR protein that is able to bind negative
and/or positive cis-acting regulatory sequences
preventing activation of nearby weak splice sites. This antagonistic
activity differs significantly of that of hnRNP A1 whose ratio to
SF2/ASF specifies the selection of alternative 5'
splice sites (Mayeda and Krainer 1992
) or mutually exclusive exons and
modulates exon skipping and inclusion (Mayeda et al. 1993
). Although
the mechanisms by which hnRNP A1 and SF2/ASF modulate the
use of alternative 5' splice sites remain poorly understood, it
might involve an intrinsic hnRNP A1 activity that can facilitate the
rapid annealing of complementary RNA molecules that is, between the
5' end of U1 snRNA and 5' splice site, as well as specific recognition of pre-mRNA sequences via the RRM domains of hnRNP A1
(Mayeda et al. 1994
). RSF1 also requires its RRM domain for activity
and this domain might even recognize the same sequence as SR proteins
but its GRS domain, shown to be essential for splicing repression in
vitro, represents a new module acting against the RS domain that has
been shown to function as activator of pre-mRNA splicing (Graveley and
Maniatis 1998
). The modular structure of RSF1 and SR proteins
strengthen the correlation between splicing and transcription factors,
proposed by Graveley and Maniatis, as both factors contain separable
nucleic acid binding and activation or repression domains.
In a given tissue small changes in the RSF1/SR
equilibrium could have profound effects on binding site occupancy by
either factor and thereby regulate splice-site selection. In this
context, it may be relevant that exonic purine-rich sequences have been observed near weak splice sites of many cellular and viral pre-mRNAs that are subject to alternative splicing (Katz and Skalka 1990
; Lavigueur et al. 1993
; Sun et al. 1993b
; Watakabe et al. 1993
; Xu et
al. 1993
; Caputi et al. 1994
; Dirksen et al. 1995
; Ramchatesingh et al.
1995
; Staffa and Cochrane 1995
; Staffa et al. 1997
). Although in most
cases, these elements stimulate splicing of the upstream intron or
inclusion of an internal exon, there are exceptions to this rule in
which purine-rich elements have been shown to serve as splicing
repressors (Kanopka et al. 1996
; McNally and McNally 1996
). The binding
of RSF1 to ESE (E. Labourier, E. Allemand, S. Brand, M. Fostier, J. Tazi, and H.-M. Bourbon, unpubl.) could be a way to mediate splicing
repression to prevent activation of cryptic splice sites within large
exons. In agreement with this hypothesis, it has been shown recently
that RSFc, a protein in the dipteran Chironomus tentans
homologous to RSF1, binds extensively to newly transcribed BR1
and BR2 premRNAs, which contain a huge exon 4 of 30-35 kb
but much less to the BR3 pre-mRNA, which largely consists of
intron sequences (L. Wieslander, pers. comm.).
In vivo experiments are expected to illuminate our findings to provide
a rationale to explain how alternative fates of a wide variety of
pre-mRNAs can be controlled by a small set of evolutionarily conserved
antagonistic sequence-specific splicing factors whose levels or
activities may be regulated according to tissue or developmental stages. Consistently, targeted expression in Drosophila of
transgenes encoding either the SR protein B52/SRp55 or
RSF1 led to pronounced deleterious effects on development (Kraus and
Lis 1994
; this work). Different severities of phenotype were observed
depending on levels of transgene expression, both for
B52/SRp55 and for RSF1 (Table 1). Strikingly the effects
of the proteins depend on their relative levels as when both proteins
were overexpressed in the same tissue the mutant phenotypes were
reverted partially or completely. For instance, >90% of progeny
from crosses between GMR-GAL4 and
UAS-RSF13 or UAS-B52 lines were unable to
eclose (Table 1). In sharp contrast, the crosses of transgenic flies
carrying both a UAS-B52 and an UAS-RSF13
element with GMR-GAL4 line led to 50% viability.
Furthermore, overexpression of B52/SRp55 restored
viability to flies overexpressing RSF1 under the control of another
tissue-specific enhancer, the imaginal disc-specific enhancer of the
scabrous gene (compare UAS-RSF16/sca-GAL4 and
UAS-B52/+; sca-GAL4/+ to UAS-B52/+;
sca-GAL4/UAS-RSF16),
implying that B52/SRp55 could have opposing effect to
RSF1 in different tissues. These phenotypes cannot be attributed to low
levels of expression of either RSF1 or B52/SRp55 mRNAs in the progeny of double-insert lines compared to the progeny of single-insert lines, as these levels were the same (Fig. 7C, panels II,
III). Instead, these results support a model in which RSF1 and
RSF1-related proteins function as SR-protein antagonists. At this time,
we cannot prove that this antagonistic effect is actually a result of
competition between a splicing repressor and a splicing activator for
the selection of correct splice sites in vivo, although the large body
of in vitro work makes this a likely conclusion. By preventing weak
and/or cryptic splice sites activation by high levels of
SR proteins, RSF1 is expected to restore correct splicing of essential
genes for Drosophila development. Therefore, our in vivo work
paves the way toward a molecular genetic analysis of the biological
role of RSF1, which might allow to uncover factors modifying the
activity of RSF1 and SR proteins.
| |
Materials and methods |
|---|
|
|
|---|
Oligonucleotides
The sequences of the synthetic oligonucleotides (Isoprim SA,
Toulouse, France) used in this study as cloning adapters or PCR primers
are (sequence is given 5'
3') 21Gex,
GCAAGCTTGGTGATCAGCGCGGGACAC; F47, CGCCAGGGTTTTCCCAGTCACGAC;
ADA1, GATCCCCGGTCAGAATTCAAGCTTATCGATGAGCTCT; ADA2,
AGCT-AGAGCTCATCGATAAGCTTGAATTCTGACCGGG; 21H1,
CTAGATTAGTTGGCGCTGCTGTGATGATGATGATGATGGCTGCTGCCGAAT; 21H2,
CGATTCGGCAGCAGCCATCATCATCATCATCACAGCAGCGCGCCAACTAAT;
21ADA1,GATCTCAAAAGGGCGGCCACGCCAT; 21ADA2,
CGATGGCGTGGCCGCCCTTTTGA; 1RBP1, CTTGGATCGCAATCGACATAGG;2RBP1, CACATATGCCGCGATATAGGGAG; HB2T1, GATCCC-GTCGTTGTCGTCGTTGTCGTCGTTGCAAGGGT; HB2T2,CTACCCTTGCAACGACGACAACGACGACAACGACGG; UAS1,
GTAACCAGCAACCAAGTAAATCAAC;21F2, TCCCCCTCCAGATCATCCTT; B52A,
AACAACCACACCGTTCGCCAAGC; copiaS, GGGCTCTTTTAGCCGAGCAAG; and copiaA, CGCAGCGCCAGTTGCGACG.
Recombinant proteins, plasmids, and purification
The IPTG-controlled GST expression system (Smith and Johnson 1988
)
was used to produce RSF1 fusion proteins. A 1.1-kb
HindIII-XbaI fragment from pNB21/5.3R
[a RSF1 cDNA insert cloned into the pNB40 vector (Brand et
al. 1995
)] was subcloned into pBluescript II (KS
) between the
HindIII and XbaI sites, to yield the p11HX1 plasmid.
The p11HX1 plasmid was in turn used as a template in a PCR with
Taq DNA polymerase (Boehringer Mannheim) to amplify the entire
RSF1 open reading frame (ORF). A HindIII site was
introduced at the 5' end by using the 21Gex oligonucleotide and the
pBluescript sequencing primer F47. Amplified DNA was cut with
HindIII and SacI and inserted into the bacterial GST
fusion protein expression vector pHBGex between the unique
HindIII and SacI sites, to yield the pGex21
expression plasmid. The pHBGex plasmid was derived from pGexA (Valle et
al. 1993
) by inserting a BamHI-HindIII adaptor made
of the two complementary oligonucleotides ADA1 and ADA2 between the
BamHI and HindIII sites (note that the original
HindIII site has been destroyed). The RSF1 ORF was
entirely sequenced to verify its integrity by using a set of synthetic
oligonucleotides. To allow for expression of a doubly tagged fusion
protein (termed GST-RSF1) with a hexahistidine-based carboxy-terminal
affinity tag, a ClaI-XbaI adaptor, made of the two
complementary oligonucleotides 21H1 and 21H2, was inserted between the
unique ClaI and XbaI sites of pGex21, to yield the
pGex21HP1 plasmid. To allow for expression of a doubly tagged fusion
protein (termed GST-RSF1
C) with most of the GRS domain deleted, a
BglII-ClaI adaptor made of the two complementary
oligonucleotides 21ADA1 and 21ADA2, was introduced between the unique
BglII and ClaI sites of pGex21HP1 (substituting a
360-bp fragment), to yield the pGex21HPN1 plasmid. To allow for
expression of a doubly tagged fusion protein (termed GST-RSF1
N) with amino-terminal RRM-containing domain deleted, pGex21HP1 plasmid DNA was cut with EcoRI and BglII and religated
(eliminating a 235-bp fragment) after end filling with the Klenow
fragment of E. coli DNA polymerase I and dNTPs, to yield the
pGex21HPC1 plasmid. The GST-RBP1 fusion was produced from the pGexRBP1
plasmid, which was constructed as follows. The entire coding sequence
of RBP1 was PCR amplified from cDNA prepared from poly(A)+
RNAs extracted from 4- to 8-hr-stage embryos, by using two specific oligonucleotides, termed 1RBP1 and 2RBP1. The resulting 520-bp PCR
product was cut with NdeI and EcoRI and inserted into
a derivative of pHBGex (H.-M. Bourbon, unpubl.). The RBP1 ORF
was entirely sequenced to verify its integrity with respect to the
original sequence.
To allow for expression of an hexahistidine-tagged version of the GRS domain of RSF1 (termed RSF1 GRS protein) a 360-bp NcoI-XbaI fragment from the pGex21HP1 plasmid was inserted into the T7-based expression vector pET-14b (Novagen) cut with NcoI and NheI.
To obtain hexahistidine-tagged SF2/ASF proteins,
wild-type or truncated versions of SF2/ASF cDNA (provided
by J. Manley, Columbia University, New York, NY) were fused in-frame by
PCR amplification in pTrcHisA (Invitrogen), using oligonucleotides
whose sequences are available upon request (Labourier et al. 1998
).
To overexpress GST fusion proteins, BL21 cells (Novagen) freshly
transformed with pGex21HP1, pGex21HPN1, pGex21HPC1, pGexRBP1, or pHBGex
(as a control) were grown under strong agitation into 2TY medium (16 grams/liter tryptone, 10 grams/liter yeast
extract and 5 grams/liter NaCl; pH was adjusted to 7 with
NaOH) at 37°C to an absorbance of 0.8 at 600 nm in the presence of
100 µg/ml ampicillin.
Isopropyl-
-d-THIOGALACTOPYRANOSIDE (IPTG) WAS ADDED TO 1 MM and incubation was continued for an additional 3 hr.
Bacteria were harvested, frozen in dry ice for 30 min, stored at
80°C, partially thawed on ice (~15 min), and quickly
resuspended in one-fifth volume of MTPBS (150 mM NaCl, 16 mM Na2HPO4 and 4 mM NaH2PO4; pH was adjusted to 7 with NaOH). All
subsequent steps were carried out at 4°C. One-tenth volume of a
freshly made 10 mg/ml lysozyme (Sigma) solution was
added. After a 30-min incubation, cells were harvested by
centrifugation (5000 rpm in an SS-34 Sorvall rotor for 5 min at
4°C). The cell pellet was resuspended in the same volume of MTPBS
supplemented with 10 mM dithiothreitol (DTT; Sigma) and 1%
Tween 20 (Bio-Rad). One-milliliter aliquots were subjected to
sonication at 4°C until the viscosity was reduced to that of buffer,
and lysates were incubated on ice for 1 hr. The bacterial debris and
insoluble materials were removed by centrifugation (12,000 rpm in a
microcentrifuge for 5 min at 4°C), and supernatants were frozen in
dry ice and stored at
80°C. Supernatants were thawed on ice and
incubated for 30 min with one-twentieth volume of a 50%
glutathione-Sepharose bead suspension (Pharmacia) equilibrated in
MTPBS. The beads were pelleted and the same volume of the 50% bead
suspension was added to the supernatant and incubated as above. Both
sets of beads were mixed and washed three times with 10-bed volumes of
MTPBS. GST or fusion proteins were eluted off the beads by two washes
with two bead volumes of 20 mM reduced glutathione (Sigma) in
120 mM KCl and 100 mM Tris-HCl at pH 7. Aliquots of
purified proteins were stored at
80°C.
His-tagged recombinant proteins were expressed in TG1 (SF2/ASF, SF2/ASF
RS, and SF2/ASF RS) or BL21 (RSF1 GRS) bacteria and purified from
inclusion bodies as described (Labourier et al. 1998
).
Total SR proteins and SRp30 protein were purified from HeLa cells or
calf thymus as described (Zahler et al. 1992
). Purified U1 snRNP from
HeLa cells was provided by R. Lührmann (Philips University,
Marburg, Germany).
In vitro transcription, splicing assays, gel filtration, and U1 snRNP-pre-mRNA binding experiments
Radiolabeled RNAs were synthesized by in vitro transcription in
presence of 20 units of SP6 RNA polymerase (Boehringer), 1 µg of
the suitable linearized plasmids, and 5 µM
[
-32P]UTP (400 Ci/mmole) in 25-µl
reactions according to the manufacturers. All in vitro transcripts were
purified by denaturing polyacrylamide-urea gels and quantitated by
Cerenkov counting.
The single-intron human
-globin construct
pSPH
-3A was derived from pSP64H
6 (Krainer et al. 1984
)
by inserting the HB2T1/HB2T2 AccI-BamHI adapter between the AccI (in the
second exon) and BamHI (from pSP64) sites. The splicing
reactions were done under standard conditions for 1.5 hr in a total
volume of 20 µl containing 50-fmole labeled pre-mRNA and 6 µl
of HeLa nuclear extract (Dignam et al. 1983
) complemented with buffer
D. Purified proteins diluted in buffer D were incubated in HeLa nuclear
extract for 5 min at room temperature before addition of radiolabeled
pre-mRNA. Splicing products were analyzed by electrophoresis on
denaturing 7% (Fig. 2A) or 6% (Fig. 2B) polyacrylamide gels and
revealed by autoradiography.
Gel-filtration chromatography was done essentially as described
previously (Michaud and Reed 1991
; Staknis and Reed 1994
). Complex
assembly reactions were incubated for 30 min at 30°C in a total
volume of 250 µl containing 75 µl of HeLa nuclear extract (Dignam et al. 1983
), 1-pmole labeled pre-mRNA, and either purified SRp30 (3.5 µl, 210 pmole) or GST-RSF1 (20 µl, 260 pmoles).
Reactions were then applied to a 2.5 × 60-cm column filled with
Sephacryl S-500 equilibrated in buffer D (Dignam et al. 1983
), and 2-ml fractions were collected at a flow rate of 2 ml/hr for Cerenkov counting.
SF2/ASF and U1 snRNP complex formation assays were
performed as described previously (Kohtz et al. 1994
) in 20 mM HEPES at pH 7.6, 5% glycerol, 100 mM KCl, 0.2 mM EDTA, and 1.5 mM MgCl2. Before loading
half of the mixtures onto native gels, heparin and glycerol were added
to a final concentration of 1 mg/ml and 15%, respectively.
Protein-protein interaction studies
For GST-binding assays, purified GST-RSF1 or GST-RSF1
C (150 pmoles each) were bound to 20 µl of glutathione-Sepharose beads in
buffer D for 15 min at room temperature. After two washes with buffer
D, beads were then incubated with an excess of SF2/ASF RS
or RSF1 GRS protein (300 pmoles each) for 30 min at room temperature and washed extensively with buffer D. Proteins were eluted by boiling
for 5 min in SDS-loading buffer and analyzed on a 12% SDS-polyacrylamide gel. Proteins were revealed by Coomassie blue staining.
For Far-Western analysis, purified recombinant proteins (~1 µg
of each), HeLa purified SR proteins (2 µg) previously treated with
50 units of calf intestinal alkaline phosphatase for 1 hr at 30°C
(to dephosphorylate them and improve their detection by labeled
probes), or purified U1 snRNP (3 µg) were run on a 12% SDS-polyacrylamide gel and transferred to nitrocellulose by
electroblotting for 90 min in 10 mM CAPS transfer buffer at
pH 11.0, containing 10% methanol. To renature the proteins, the
filters were treated as described previously (Kohtz et al. 1994
) and
probed with 10 µg of labeled SF2/ASF or GST-RSF1 in
10 ml of binding buffer (Kohtz et al. 1994
). To label
SF2/ASF and GST-RSF1, 10 µg of each purified recombinant protein was incubated with 800 units of purified starfish cdc2 protein kinase (a generous gift from M. Dorée laboratory, CNRS, Montpelier, France) in the presence of 20 µCi of
[
-32P]ATP and 1 µM of cold ATP in buffer
B (Labourier et al. 1998
) for 1 hr at 30°C. Unreacted nucleotides
and cdc2 kinase were removed by binding labeled SF2/ASF
or GST-RSF1 to nickel-agarose beads or glutathione-Sepharose beads,
respectively. After extensive washings of the beads with buffer B,
labeled proteins were eluted with either 1 M imidazole for
SF2/ASF or 20 mM glutathione for GST-RSF1.
Drosophila stocks
The UAS-RSF1 construct was made as follows: a 1.15-kb
XbaI-XhoI RSF1 cDNA fragment, prepared from
p11HX1 (see above), was subcloned into the XhoI and
XbaI sites of the pUAST vector (Brand et al. 1994
). This
pUAST-RSF1 DNA was used to transform w1118 flies
according to standard protocols (Spradling and Rubin 1982
), except that
injections employed nondechorionated embryos. Fifteen independent
UAS-RSF1 transgenic lines were established. The transposon integration sites were mapped to individual chromosomes by standard crosses using balancer stocks. Three homozygous viable lines (3, 5, and
6) were used in this report. These transformed flies were crossed to
homozygous (GMR-GAL4, sca-GAL4, or
da-GAL4) GAL4-expressing lines and scored for phenotypes
under a stereomicroscope. Most GAL4 lines were from the
Bloomington Stock Center. The sca-GAL4 line (Y.N. Jan,
unpubl.) was provided by M. Vervoord (CNRS, Toulouse, France). All
flies were reared at 18-28°C on standard medium. Homozygous double
insert lines were obtained by standard crosses using balancer stocks.
Determination of UAS-RSF1, UAS-B52 transgene expression and developmental Northern blot analysis
Total RNAs or proteins were purified from 20 larvae of the following genotypes: (GMR-GAL4/+; UAS-lacZ/+), (GMR-GAL4/+; UAS-RSF13/+), (GMR-GAL4/UAS-B52) and (GMR-GAL4/UAS-B52; UAS-RSF13/+) with 1 ml of Trizol reagent (GIBCO-BRL). RNAs were treated subsequently with 2 units of RQ1 DNase (Promega) for 15 min at 34°C and quantitated by UV absorbance determination. Reverse transcriptions were carried out with 400 units of M-MLV reverse transcriptase (GIBCO-BRL), 5 µg of total RNA, and 350 µg of poly(dT)15 primer in a final volume of 50 µl. PCRs were performed with 1.25, 2.5, or 5 µl of the RT reactions, 20 pmole of each primer (UAS1 and 21F2 for UAS-RSF1, UAS1 and B52A for UAS-B52, copiaS and copiaA for the Drosophila retrotransposon copia), 100 µM dNTP, 1 mM MgCl2, 2.5 units of Taq DNA polymerase (GIBCO-BRL), and 2 µCi [µ-32P] dCTP in a final volume of 50 µl. After 20 cycles of PCR (30 sec at 60°C, 1 min at 72°C, 30 sec at 95°C), 2 µl of each PCR reaction was boiled for 3 min, loaded onto a 5% denaturing polyacrylamide gel, and amplified fragments were revealed by autoradiography.
Total proteins from transgenic larvae or HeLa nuclear extract (~30
µg) were run on 12% SDS-polyacrylamide gels and transferred to
nitrocellulose by electroblotting for 90 min in 10 mM CAPS transfer buffer (pH 11.0), containing 10% methanol. Blots were probed
with mAb104 (Roth et al. 1991
). A horseradish peroxidase-conjugated anti-mouse IgM (Sigma) and the ECL reagent (Amersham) were used for
visualization of mAb104-reactive proteins.
Northern blot analysis was done as described (Brand and Bourbon 1993
)
using the largest RSF1 cDNA insert (Brand et al. 1995
) as a probe.
| |
Acknowledgments |
|---|
We are grateful to J. Steitz for helpful comments on the
manuscript. We thank J. Lis, M. Vervood, and the Bloomington Stock Center for fly strains, R. Lührmann for purified U1 snRNP and PIP7 constructs, M. Dorée for purified cdc2 kinase, J. Stèvenin for HeLa-purified SR proteins, J. Manley for
SF2/ASF cDNA, and A. Krainer for providing
pSP64H
6 construct. H.-M.B. acknowledges F. Amalric and A. Vincent for their interest as well as logistical support in the initial
part of this work. We thank D. Cribbs for support, scientific interest,
and critical review of the manuscript. A special thanks to A.-M. Duprat
for her constant support. We also thank Y. De Preval for synthesizing a
number of oligonucleotides and, C. Ardourel and A. Lepage for help in
injection of embryos. This work was supported by an Action
Thématique Incitative sur Programme et Equipes (ATIPE) grant from
the CNRS (to H.-M.B.) and a grant from the CNRS and the Association
pour le Recherche sur le Cancer (ARC) (to J.T.). E.L and E.A. were
supported by graduate fellowships from the Ministére de l'
Enseignement Supérieur et de la Recherche (MESR); E.L. and I.G.
benefited from a graduate training fellowship from the ARC and
Foundation pour le Recherche Médicale (FRM), respectively.
The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked `advertisement' in accordance with 18 USC section 1734 solely to indicate this fact.
| |
Footnotes |
|---|
Received September 25, 1998; revised version accepted January 28, 1999.
Present addresses: 3Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut 06536-0812 USA; 4Department of Biological Sciences, University of Manchester, Manchester, M13 9PT, UK.
5 These authors have contributed equally to this work.
6 Corresponding author.
E-MAIL tazi{at}igm.cnrs-mop.fr; FAX (33) 04 67 04 02 45.
| |
References |
|---|
|
|
|---|